Brief: Formosa Pharmaceuticals And Aimmax Therapeutics Receive FDA Approval For Clobetasol Propionate Ophthalmic Suspension 0.05%
04/03/2024 22:59
March 4 (Reuters) - Formosa Pharmaceuticals Inc:
* FORMOSA PHARMACEUTICALS AND AIMMAX THERAPEUTICS RECEIVE
FDA
APPROVAL FOR CLOBETASOL PROPIONATE OPHTHALMIC SUSPENSION 0.05%,
FOR THE TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN
FOLLOWING OCULAR SURGERY
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Formosa Pharmaceuticals
See all newsBrief: Formosa Pharmaceuticals Announces Licensing Agreement With Rxilient
Brief: Harrow Acquires U.S. Commercial Rights To Byqlovi™ From Formosa Pharmaceuticals
US FDA approves Eyenovia's eye drug, Formosa Pharma says (updated)
US FDA approves Eyenovia's eye drug, Formosa Pharma says
Brief: Formosa Pharmaceuticals And Aimmax Therapeutics Receive FDA Approval For Clobetasol Propionate Ophthalmic Suspension 0.05%